Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer

Monoclonal antibody-based targeted therapies have greatly improved treatment options for patients by binding to the innate immune system. However, the long-term efficacy of such antibodies is limited by mechanisms of drug resistance. Over the last 50 years, with advances in protein engineering techn...

Descripción completa

Detalles Bibliográficos
Autores principales: Huan, Tian, Guan, Bugao, Li, Hongbo, Tu, Xiu, Zhang, Chi, Tang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Immunotherapy - Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543353/
https://www.ncbi.nlm.nih.gov/pubmed/37772505
http://dx.doi.org/10.1080/21645515.2023.2256904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543353/
https://www.ncbi.nlm.nih.gov/pubmed/37772505
http://dx.doi.org/10.1080/21645515.2023.2256904

Ejemplares similares